Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (SE:CANTA)
:CANTA
CANTA Stock Chart & Stats
kr5.47
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr5.47
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.00 - kr6.59
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
kr1.36B
Enterprise Valuekr1.02B
Total Cash (Recent Filing)kr339.14M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)10.8
Beta0.67
Next Earnings
Feb 20, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr13.97Price Target Upside155.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad Clinical Opportunity For Lead AssetNadunolimab's IL1RAP-targeting mechanism being evaluated across pancreatic, non-small cell lung and colorectal cancers creates multiple clinical pathways that could expand patient reach if tumor-priming activity enhances checkpoint inhibitor responses.
Partner Validation And Non-dilutive FinancingOtsuka's acquisition of the CAN10 program validates the IL1RAP approach and provides non-dilutive financing plus milestone and royalty upside, enabling Cantargia to reallocate resources to core pipeline programs.
Pivotal Readiness And Companion Diagnostic DevelopmentNadunolimab's advancement toward pivotal development and the use of an IL1RAP companion diagnostic positions the program to enter a biomarker-driven first-line pancreatic cancer study with better patient selection.
Bears Say
Challenging Colorectal Trial PopulationTargeted colorectal cancer populations have historically been non-responsive to immunotherapy, which raises the bar for demonstrating a clear clinical benefit for nadunolimab in that indication.
Confirmed Failure In Triple-negative Breast CancerFinal TRIFOUR survival and response data confirmed lack of efficacy of nadunolimab in triple-negative breast cancer, eliminating that potential commercial opportunity.
Valuation And Program-risk PressureNegative Phase 2 TRIFOUR results justify prior analyst zero valuation for the TNBC program and may pressure overall company valuation until positive readouts emerge in core indications.
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.00 and its highest was kr6.59 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is kr1.36B.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 18 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Nov 19, 2025. The company reported kr1.07 earnings per share for the quarter, beating the consensus estimate of -kr0.17 by kr1.24.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.19.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of kr1.07 in its last earnings report, beating expectations of -kr0.17. Following the earnings report the stock price went down -7.445%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
CANTA Stock 12 Month Forecast
Average Price Target
kr13.97
▲(155.32% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―